Rationale for fixed-dose combinations in the treatment of hypertension: The Cycle Repeats

Drugs

Volumn 62, Issue 3, 2002, Pages 443-462

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTALBITAL; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DIHYDRALAZINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; EPHEDRINE; HEXAMETHONIUM BROMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; METHYLDOPA; MINOXIDIL; POTASSIUM SPARING DIURETIC AGENT; RAUWOLFIA ALKALOID; RESERPINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL PLUS VERAPAMIL; TRIAMTERENE; UNINDEXED DRUG;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ELECTROLYTE DISTURBANCE; HEALTH CARE POLICY; HISTORY OF MEDICINE; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SODIUM RETENTION; TREATMENT OUTCOME; WATER RETENTION;

RAUVOLFIA;

EID: 0036189466     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262030-00003     Document Type: Review

References (117)

1. History of fixed-dose combination therapy for hypertension
2. Fixed dose combination antihypertensive therapy: Is this the future?
3. Fixed-dose combination antihypertensive drugs. Do they have a role in rational therapy?
4. Newer approaches to antihypertensive therapy
5. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
6. International Society of Hypertension guidelines for the management of hypertension
7. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP)
8. Maximizing cardiorenal benefit in the management of hypertension: Achieving blood pressure goals
9. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
10. Hypertension Optimal Treatment (HOT) study: Successes and failures
11. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
12. Effects of blood pressure control on progressive renal disease in blacks and whites
13. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
14. The heterogeneity of hypertension: Why doesn't every patient respond to every antihypertensive drug
15. Single drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo
16. Management guidelines for hypertension: Is anyone taking notice?
17. Felodipine/metoprolol: A review of the fixed dose controlled release formulation in the management of essential hypertension
18. Fixed-dose combination vs monotherapy in hypertension: A meta-analysis evaluation
19. Comparison of different fixed antihypertensive combination drugs: A double-blind, placebo-controlled parallel group study
20. Pharmacological basis for combination therapy of hypertension
21. Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease
22. Kinetics of angiotensin converting enzyme inhibitors in renal failure
23. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency
24. The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: Focus on fixed-dose combination antihypertensive therapy
25. Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension
26. Diuretic combinations in refractory edema states: Pharmacokinetic-pharmacodynamic relationships
27. Pretreatment with enalaprilat blunts nicardipine-induced sympathetic activation in spontaneously hypertensive and Wistar-Kyoto rats
28. Converting enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine
29. Dose-response relationships in antihypertensive treatment
30. Serum magnesium and potassium levels in hypertensive patients after a therapeutic switch from hydrochlorothiazide plus a potassium supplement to Maxzide
31. Potassium/magnesium depletion in patients with cardiovascular disease
32. Response of thiazide-induced hypokalemia to amiloride
33. Enalapril-felodipine ER in essential hypertension: A factorial design study of combination therapy
34. The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: Different effects of enalapril and hydrochlorothiazide
35. Treatment of patients with essential hypertension: Amlodipine 5mg/benazepril 20 mg compared with amlodipine, benazepril 20 mg, and placebo
36. Population trends in antihypertensive drug use: Results from the MONICA Augsburg Project 1984 to 1995
37. An overview of antihypertensive therapy in the 20th century
38. Remembering the lessons of basic pharmacology
39. Treating the individual hypertensive patient: Considerations on dose, sequential monotherapy and drug combinations
40. Fixed-dose combination antihypertensive drugs: Principles and practice
41. Low-dose fixed-combination antihypertensive therapy
42. Combination products as first-line pharmacotherapy
43. Fixed dose combinations of ACE inhibitors
44. The effect of prescribed daily dose frequency on patient medication compliance
45. Medication compliance for antihypertensive therapy
46. Comparison and interaction of low dose felodipine and enalapril in the treatment of essential hypertension in elderly subjects
47. A clinical trial evaluating the 24-hour effect of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension
48. Low-dose antihypertensive combination therapy; its rationale and role in cardiovascular risk management
49. Self-reported hypertension treatment practices among primary care physicians
50. Prevalence of hypertension in the US adult population. Result from the Third National Health and Nutrition Examination Survey, 1988-1991
51. Managing hypertension in general practice: Can we do better?
52. Antihypertensive drug trials, contributions from medical monitors
53. When outpatient drug treatment fails: Identifying noncompliers as a cost containment tool
54. Captopril and hydrochlorothiazide: Rationale for their combination
55. Response surface and factorial designs for combination antihypertensive drugs
56. Calcium antagonists-ACE inhibitors combination therapy: Objectives and methodology of clinical development
57. Combination therapy with diuretics: An evolution of understanding
58. Spironolactone in thiazide-induced hypokalemia: Variable response between patients
59. Old antihypertensive agents- diuretics and betablockers: Do we know how and in whom they lower blood pressure?
60. A single-blind, comparative study of hydrochlorothiazide/amiloride ('Moduretic' 25) and hydrochlorothiazide/triamterene ('Dyazide') in elderly patients with congestive heart failure
61. Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol
62. Diuretic therapy for hypertension and the risk for primary cardiac arrest
63. Lack of effect of beta-blocker on flat dose response to thiazide combined with beta-blocker
64. Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol
65. A multifactorial trial design to assess combination therapy in hypertension
66. Low-dose drug combination therapy: An alternative first-line approach to hypertension treatment
67. Veterans Administration Cooperative Study Group on antihypertensive agents: Propranolol in the treatment of essential hypertension
68. A comparison of the efficacy and safety of a β-blocker, a calcium-channel blocker, and a converting enzyme inhibitor in hypertensive blacks
69. Use of β-adrenergic receptor blockers in blacks
70. Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension
71. Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP)
72. Lessons from combination therapy in Veterans Affairs Studies
73. Low-dose drug combination therapy: An alternative first-line approach to hypertension treatment
74. Felodipine-metoprolol combination tablet: A valuable option to initiate antihypertensive therapy
75. Oxidation of dihydropyridine calcium channel blocker and analogs by human liver cytochrome P-450 IIIA4
76. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations
77. Ambulatory 24-hr blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension
78. Comparison of a felodipine-metoprolol combination tablet vs each component alone as antihypertensive therapy
79. Enalapril with either a 'very low' or 'low' dose of hydrochlorothiazide is equally effective in essential hypertension. A double blind trial in 100 essential hypertensives
80. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination: A large multicenter study
81. Losartan with hydrochlorothiazide in the treatment of hypertension
82. Angiotensin converting enzyme inhibitors in the treatment of hypertension
83. Ramipril and hydrochlorothiazide combination therapy in hypertension: A clinical trial of factorial design
84. Captopril and oxprenolol in a fixed combination with diuretics; comparison of their antihypertensive efficacy and metabolic effects
85. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide
86. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension
87. Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide - A randomized controlled trial
88. An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension
89. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan
90. Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide
91. Potentiation of the antihypertensive effect of enalapril by randomised addition of different doses of hydrochlorothiazide
92. The efficacy and tolerability of enalapril in a formulation with a very low close of hydrochlorothiazide in hypertensive patients resistant to enalapril monotherapy
93. Controlled multicentre study of antihypertensive effects of lisinopril, hydrochlorothiazide, lisinopril and hydrochlorothiazide, in the treatment of 394 patients with mild to moderate essential hypertension
94. Long-term efficacy of a new, fixed, very low-dose angiotensin-converting enzyme inhibitor/diuretic combination as first-line therapy in the elderly hypertensive
95. Quinapril and hydrochlorothiazide combination for control of hypertension: Assessment by factorial design
96. Fixed low-dose combination therapy in hypertension - A dose response study of perindopril and indapamide
97. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension
98. Clinical overview of irbesartan: A new angiotensin II receptor antagonist
99. A diuretic is more effective than a β-blocker in hypertensive patients not controlled on amlodipine and lisinopril
100. A 'lipo-protectve' effect of a fixed combination of captopril and hydrochlorothiazide in antihypertensive therapy
101. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects
102. Blood pressure effects of the angiotensin-II receptor blocker, losartan
103. Renal effects of felodipine in hypertension
104. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: A randomized, double-blind, placebo-controlled, parallel-group study
105. Combination drug therapy with calcium-channel blockers in the treatment of systemic hypertension
106. Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension
107. Effects of combination therapy on the heart
108. When antihypertensive monotherapy fails: Fixed-dose combination therapy
109. The role of combination antihypertensive therapy and the progression of renal disease hypertension: Looking toward the next millenium
110. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
111. Diuretics: Where have we been and where are we going?
112. The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers
113. Angiotensin converting enzyme inhibitor - Calcium antagonist combination: An alliance for cardioprotection
114. Calcium channel blockade with nifedipine and angiotensin-converting enzyme inhibition with captopril in the therapy of patients with severe primary hypertension
115. The rationale for combination versus single-entity therapy in hypertension
116. Safety profile of the combination of verapamil and trandolapril